Pneumococcal Polysaccharide Conjugates for Infant Immunogenicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current multivalent pneumococcal conjugate vaccines have limitations in serotype coverage, with emerging serotypes not included in existing vaccines leading to increased prevalence of pneumococcal diseases, necessitating the identification and characterization of new serotypes for inclusion in future vaccines.
Innovation Solution
Purified capsular polysaccharides from Streptococcus pneumoniae serotype 31 and polysaccharide-protein conjugates are developed, with a specific repeating unit structure, allowing for the production of immunogenic compositions that can be incorporated into multivalent vaccines, including serotypes not previously covered.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If unconjugated pneumococcal polysaccharides are used in vaccines, then the vaccine can be manufactured with simpler processes, but infants and young children respond poorly to these unconjugated polysaccharides
Solution Approach 1:
The patent applies composite materials by chemically conjugating bacterial polysaccharide immunogens to carrier proteins (such as tetanus toxoid or diphtheria toxoid). This creates a composite structure where the polysaccharide component provides serotype-specific immunity while the protein component provides T-cell-dependent immunogenicity, enabling effective immune responses in infants and young children that neither component could achieve alone.
2Device complexity
If existing multivalent pneumococcal conjugate vaccines cover only certain serotypes, then the vaccine formulation remains manageable, but emerging serotypes not included in the vaccine lead to increased prevalence of pneumococcal diseases
Solution Approach 1:
The patent applies universality by developing a platform technology for creating conjugate vaccines that can be adapted to cover multiple pneumococcal serotypes. The same conjugation methodology and carrier proteins can be used across different serotypes, allowing the vaccine system to be universally applied to protect against both current and emerging serotypes without requiring entirely new formulations.
Solution Approach 2:
The patent applies segmentation by addressing serotype coverage in modular units - each serotype can be individually characterized, purified, and conjugated to carrier protein as a separate module. This allows flexible combination of different serotype-specific polysaccharide-protein conjugates into multivalent vaccines that can be updated to include emerging serotypes without redesigning the entire vaccine system.
3Productivity
If the polysaccharide structure is not correctly identified, then vaccine development can proceed with existing structural assumptions, but the resulting conjugates may have reduced immunogenicity or efficacy
Solution Approach 1:
The patent applies preliminary action by performing comprehensive structural characterization of pneumococcal polysaccharides (including serotype 31) before proceeding to conjugate vaccine development. This includes determining the complete repeating unit structure, linkage types, and stereochemistry in advance, which enables optimization of conjugation conditions and predicts immunogenicity outcomes, preventing costly revisions later in development.
Data Source
AI summary
The present invention provides capsular polysaccharides from Streptococcus pneumoniae serotypes identified using NMR. The present invention further provides polysaccharide-protein conjugates in which capsular polysaccharides from one or more of these serotypes are conjugated to a carrier protein such as CRM197. Polysaccharide-protein conjugates from one or more of these serotypes may be included in multivalent pneumococcal conjugate vaccines having polysaccharides from multiple additional Steptococcus pneumoniae serotypes.